Aurobindo gets US FDA nod for anti-infective injection

Aurobindo Pharma Limited has received final approval from the US Food and Drug Administration(USFDA) to manufacture and market Levofloxacin in 5 per cent Dextrose injection.

The drug is expected to be launched in the first quarter of the next financial year.

The product is an anti-infective used in the treatment of bacterial infection in adults, according to the company.

Levofloxacin in 5 per cent Dextrose Injection has an estimated market size of $46 million for the 12 months ending December 2015, according to the IMS data.

The approved abbreviated new drug application (ANDA) is bioequivalent and therapeutically equivalent to the reference listed drug product Levaquin of Janssen Pharmaceuticals, Inc.

 

 


Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel